{
  "generated_at": "2026-01-25",
  "updated_at": "2026-01-25",
  "methodology": "External validation via ClinicalTrials.gov and PubMed",
  "prioritized_candidates": {
    "tier_1_high_priority": {
      "description": "Strong model signal + moderate external evidence = potential novel repurposing",
      "candidates": [
        {
          "drug": "Sirolimus",
          "disease": "Psoriasis",
          "model_score": "High",
          "validation_score": 0.40,
          "rationale": "mTOR inhibitor. mTOR pathway implicated in psoriasis pathogenesis. Could be alternative to biologics.",
          "next_steps": ["Literature deep dive on mTOR in psoriasis", "Check for ongoing trials"]
        },
        {
          "drug": "Clopidogrel",
          "disease": "Rheumatoid Arthritis",
          "model_score": "High",
          "validation_score": 0.37,
          "rationale": "Antiplatelet agent. Emerging evidence for platelet-immune system crosstalk in RA.",
          "next_steps": ["Review platelet-inflammation research", "Assess safety profile for chronic use"]
        },
        {
          "drug": "Everolimus",
          "disease": "Rheumatoid Arthritis",
          "model_score": "High",
          "validation_score": 0.30,
          "rationale": "mTOR inhibitor already used in transplant. Shares mechanism with sirolimus.",
          "next_steps": ["Compare to sirolimus RA data", "Check for synergy with existing DMARDs"]
        },
        {
          "drug": "Metformin",
          "disease": "Breast Cancer",
          "model_score": "High",
          "validation_score": 0.21,
          "rationale": "Well-known repurposing candidate. Multiple epidemiological studies show reduced cancer risk in diabetics on metformin.",
          "next_steps": ["This is already being actively investigated - review trial status"]
        }
      ]
    },
    "tier_2_emerging": {
      "description": "Novel predictions with some literature support",
      "candidates": [
        {
          "drug": "Panitumumab",
          "disease": "Gastric Adenocarcinoma",
          "validation_score": 0.45,
          "rationale": "Anti-EGFR mAb. EGFR overexpressed in gastric cancer. Extension of CRC indication."
        },
        {
          "drug": "Olaparib",
          "disease": "Breast Cancer",
          "validation_score": 0.34,
          "rationale": "PARP inhibitor. Already approved for BRCA+ breast cancer - model capturing this."
        },
        {
          "drug": "Busulfan",
          "disease": "Plasma Cell Myeloma",
          "validation_score": 0.36,
          "rationale": "Alkylating agent used in conditioning. Some use in myeloma protocols."
        }
      ]
    },
    "tier_3_novel_unvalidated": {
      "description": "High model scores with minimal external evidence - truly novel or spurious",
      "candidates": [
        {
          "drug": "Paclitaxel",
          "disease": "Rheumatoid Arthritis",
          "model_score": 1.09,
          "validation_score": 0.0,
          "note": "Top model prediction but no trials/pubs. Mechanism unclear - needs investigation."
        },
        {
          "drug": "Teniposide",
          "disease": "Rheumatoid Arthritis",
          "model_score": 1.07,
          "validation_score": 0.0,
          "note": "Topoisomerase II inhibitor. Why RA? Possible anti-proliferative effect on synoviocytes?"
        }
      ]
    }
  },
  "false_positives": {
    "description": "Predictions that appear valid but are confounded by comorbidity or other factors",
    "candidates": [
      {
        "drug": "Digoxin",
        "disease": "Type 2 Diabetes",
        "model_score": 1.05,
        "validation_score": 0.88,
        "status": "FALSE_POSITIVE",
        "deep_dive_date": "2026-01-25",
        "reason": "Comorbidity confounding - HF patients often have T2D",
        "evidence_summary": {
          "negative": [
            "Spigset 1999: HbA1c 5-6% OFF digoxin vs 7-8% ON digoxin (worsens glucose)",
            "Mechanism: Na+/K+-ATPase inhibition reduces glucose transport into cells",
            "Animal studies: digoxin raises blood sugar"
          ],
          "neutral": [
            "DIG trial (n=6,800): No difference in diabetes onset between digoxin vs placebo"
          ],
          "misleading_trials": [
            "8 trials are mostly drug-drug interaction studies (diabetes drugs + digoxin)",
            "Heart failure subgroup analyses, not digoxin treating T2D"
          ]
        },
        "related_finding": {
          "indication": "NAFLD/NASH",
          "status": "preclinical_only",
          "note": "Mouse studies show digoxin improves fatty liver via PKM2-HIF-1a. May indirectly benefit T2D patients with NAFLD. No human trials yet."
        },
        "confounding_pattern": "CARDIAC_METABOLIC_COMORBIDITY"
      }
    ]
  },
  "confounding_patterns": {
    "description": "Known patterns that cause false positive predictions",
    "patterns": [
      {
        "id": "CARDIAC_METABOLIC_COMORBIDITY",
        "description": "Heart failure drugs appear connected to T2D/metabolic diseases because HF and metabolic syndrome frequently co-occur",
        "drugs_at_risk": ["digoxin", "furosemide", "spironolactone", "carvedilol"],
        "diseases_at_risk": ["type 2 diabetes", "obesity", "metabolic syndrome"],
        "detection": "High validation score but mechanism is antagonistic to treatment"
      },
      {
        "id": "POLYPHARMACY_INTERACTION",
        "description": "Trials exist for drug-drug interactions, not treatment efficacy",
        "detection": "Check if trials are Phase 1 PK studies rather than efficacy trials"
      }
    ]
  },
  "validation_statistics": {
    "total_validated": 100,
    "with_trials": 61,
    "with_publications": 89,
    "strong_evidence": 57,
    "moderate_evidence": 10,
    "weak_evidence": 23,
    "no_evidence": 10,
    "confirmed_false_positives": 1
  },
  "key_findings": [
    "57% of top predictions have strong external evidence - model is learning real patterns",
    "10% have moderate evidence - best repurposing candidates for follow-up",
    "Model correctly identifies approved indications (Cetuximab/CRC, Bevacizumab/CRC, etc.)",
    "mTOR inhibitors (Sirolimus, Everolimus) show consistent signal for autoimmune diseases",
    "CAUTION: High validation scores can be misleading - Digoxin/T2D had 0.88 score but is FALSE POSITIVE",
    "Cardiac-metabolic comorbidity is a major confounding pattern to watch for"
  ]
}
